|
|
||||||||
From the Departments of Medicine and Physiology, Cardiovascular Research Institute, University of California San Francisco, San Francisco, California.
PURPOSE. To define the role of the cystic fibrosis transmembrane conductance regulator (CFTR) in Cl secretion at the mouse ocular surface in vivo.
METHODS. Open-circuit potential differences (PDs) across the fluid-bathed ocular surface were measured in anesthetized wild-type and cystic fibrosis (CF) mice in response to Cl ion substitution and transport agonists and inhibitors.
RESULTS. Basal ocular surface PD was 23 ± 1 mV (SE; 20 wild-type mice), depolarizing to 16 ± 2 mV after amiloride, then hyperpolarizing to 34 ± 3 mV after low Cl. CFTR activation by forskolin or a selective activator caused further sustained hyperpolarization to 50 to 60 mV. UTP produced a comparable but transient hyperpolarization. The CFTR inhibitors CFTRinh-172 and GlyH-101 largely reversed agonist- but not low Cl-induced hyperpolarizations. PD in CF mice hyperpolarized by 2.1 mV after low Cl and was insensitive to CFTR activators or inhibitors.
CONCLUSIONS. CFTR provides a major pathway for mouse ocular surface Cl secretion, suggesting the application of CFTR activators as therapy for dry eye. Amiloride-sensitive Na+ transporters facilitate Na+ absorption. PD measurements provide a robust and reproducible means of assessing ocular surface ion transporting mechanisms.
This article has been cited by other articles:
![]() |
N. Yamamoto, N. Yamamoto, M. W. Petroll, J. V. Jester, and H. D. Cavanagh Regulation of Pseudomonas aeruginosa Internalization after Contact Lens Wear In Vivo and in Serum-Free Culture by Ocular Surface Cells. Invest. Ophthalmol. Vis. Sci., August 1, 2006; 47(8): 3430 - 3440. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Levin, J. K. Kim, J. Hu, and A. S. Verkman Potential Difference Measurements of Ocular Surface Na+ Absorption Analyzed Using an Electrokinetic Model Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 306 - 316. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |